For patients undergoing heart surgery, the incidence of post-operative atrial fibrillation (POAF) can be close to 50%, depending on the type of surgery and patient characteristics. ​ That makes POAF the leading complication of cardiac surgery and brings the risk of adverse acute and long-term clinical outcomes including longer hospital and ICU stay.​ What’s being explored to help those patients?​ The BoxX-NoAF trial is evaluating the safety and effectiveness of surgical ablation and left atrial appendage management in non-Afib cardiac surgery patients to reduce the incidence of POAF and long-term clinical Afib. Richard Whitlock #ClinicalTrial #Afib #cardiacsurgery

Attending #STSA2026? Stop by the AtriCure booth to learn more about the global leader in LAA exclusion, the AtriClip® device portfolio. And, discover how the Isolator Synergy EnCompass® clamp can be used alongside AtriClip during CABG procedures.